210 likes | 337 Views
EurocanPlatform A Platform of European Cancer Research Centres for Translational Research Ulrik Ringborg CancerCenter Karolinska. Cancer is increasing globally (WHO). 2008 12,4 million new cancer patients 2030 20 million new cancer patients 2008 8,3 million deaths
E N D
EurocanPlatformA Platform of European Cancer Research Centres for Translational ResearchUlrikRingborgCancerCenter Karolinska
Cancer is increasingglobally (WHO) • 2008 12,4 million new cancer patients • 2030 20 million new cancer patients • 2008 8,3 million deaths • 2030 12.9 million deaths • 2008 28 million patients living with cancer • 2030 82 million patients living with cancer
Conclusions from epidemiologicalanalyses • Cancer is one of the mainchronicdiseases • Present time trends of improvement of the mortality rate in Europe is not enough to decrease the number of cancer deaths over the nextdecades • At the same time, cancer biology & modern technologies offer new possibilities to change the negative trends
Strategies to decrease the problem • Improve prevention • Increasecure rate • Earlydetection is the bridge between prevention & therapeutics
There are, however, twomainbarriers The intrinsiccomplexity of cancer Fragmentation (research, clinicalcare, funding)
Fragmentation of cancer research – mainreasons Suboptimal translational cancer resesarch Bridgingbetweenbasic and clinical research – earlytranslational researchcan be improved Bridgingbetweenclinical research and implementation and evaluation in the clinicalcare – late translational research should be improved Lack of criticalmass Eurocanproject
Criticalmass • The Comprehensive Cancer Center (CCC) to guarantee the criticalmass for clinicalcare & infrastructures for research & education Integration of care, research and education – the linkagebetween research & innovation • Network of CCCs to guarantee the criticalmass for translational cancer research - Patients - Biological materials - Technologicalresources - Competences
A key message • Collaboration betweenindividual research groups is no longer the solution! • Collaboration betweencentres is mandatory to guaranteeinfrastructure support, criticalmass of expertise & resources, as well as to improvecoordination.
A European platform for translational cancer research The platform will bring together Comprehensive Cancer Centres with a strong research agenda with basic/preclinical Cancer Centres in an integrated network to collaborate and share resources to optimize the translational process and to increase global competitiveness * Such a platform of centres is the only possible way to reach the critical mass and sustainability that is necessary to innovate and deliver in all areas of cancer research. * The Stockholm Declaration, Molecular Oncology, 2, 2008
EurocanPlatform - NoE Structuringtranslational cancer research between cancer research centres in Europe A structure for innovative translational research on prevention, earlydetection and therapeutics The whole cancer research continuum is covered – 16 WPs * Duration of project – 5 years * 12 million euros * 28 participants from 11 countries
European Commission Project S&T Advisory Board PROJECT COORDINATORSupported by Vice Coordinator Project PanelsDisseminationTraining/EducationEthical Review IPRTechnology Transfer Project Steering Committee(1 member/partner) Scientific Steering Committee(8 members) Knowledge managementLinking all organisational groups Project OfficeManagement & Administration Executive Committee(5 members) Quality Assurance, Education & Dissemination WPs 12,13,14 (2 coordinators) Prevention & Therapeutics WPs 2,3,6(2 coordinators) Technologies WPs 4,5,7,8,9(2 coordinators) Biorepositories & Clinical Databases WPs 10,11(2 coordinators)
Project SteeringCommittee • Each partner presented by one person • WP-leader not representing the partner may be non-votingmember • Majorityrequired for decision • Meetingstwiceannualy
Role of the Project SteeringCommittee • Delegate certain areas of responsibility to the CO or ad hoc groups of consortium members. • Provide overall project management policy. • Make formal decisions on the project & project strategy. • Define, allocate and develop tasks. • Check the progress of the work. • Ensure full integration and coordination of the research teams. • Plan for change and risk management.
Roleof theProject SteeringCommittee, cont • Author and implement the Quality Assurance Plan. • Coordinate the preparation of technical reports. • Define the budgets for the individual parts of the project. • Reviewing and proposing budget reallocations • Identify potential new project partners. • Permit formal exchanges of information between the partners. • Ensure optimal use of project results. • Develop decision-making structures.
Management • Co-ordinator Ulrik Ringborg • Vice Co-ordinator Rolf Lewensohn • Project Manager Christina von Gertten • Project Administrator Evelyn Göransson • Support – Grants Office KI, Miles Davies – Legal Council at KI
Executivecommittee • Ulrik Ringborg • Rolf Lewensohn • Anton Berns • Anne-Lise Börresen-Dale • Julio Celis Day-to-dayresponsbilitiesdelegated by the Project SteeringCommittee
ScientificSteeringCommittee • Anton Berns (chairman) Alexander Eggermont • René Bernards Marco Pierotti • Carlos Caldas Ulrik Ringborg • Julio Celis Thomas Tursz
Role of ScientificSteeringCommittee • Scientificco-ordination of the project • Propose & evaluate research projects • Proposesharing of research resources • Support the scientific integration in the EurocanPlatform • Deal with legal & ethicalissues • Participate in discussions with the industry • Prioritizetraining & exchange of researchers • Work for research support & sustainability
ScientificAdvisory Board • Hedvig Hricak • Mark Israel • John Mendelsohn • Richard Schilsky
A ComprehensivePlatform for Translational Cancer Research • Increase the interaction between cancer biology & clinical research • New strategies for research on prevention, earlydetection & therapeutics • Increaseinfrastructure support & criticalmass overall • Cover the cancer research continuumincluding late translational research • Involvemethods to measure innovation prevention & cancer care
Scientific Co-ordination (WP1) and Management (WP16) Quality assurance of centres (WP12), Ethics (WP15), Education (WP13) Technological structures/resources Kinome analysis (WP4) DNA damage response (WP5) Technological resources (WP8) Bioinformatics (WP9) Biobanking (WP10) Patient data registries (WP11) ResearchPrevention (WP2) Early detection (WP3) Therapeutics (WP6) Preclinicalresearch (WP7) Implementation and evaluation of prevention and therapeutics (WP11) Dissemination (WP14)